CLASS III Drug recall · Reported 31 May 2023 · FDA Enforcement Report

Methylprednisolone Acetate Injectable Suspension recalled

Amneal Pharmaceuticals of New York is recalling Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, distributed nationwide in the US. The recall was initiated on 8 May 2023 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot Numbers: AP220481, Exp 09/2024; AP220536A, Exp 10/2024
Quantity recalled69,239 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0756-2023
FDA event ID
92249
Recalling firm
Amneal Pharmaceuticals of New York, Brookhaven, NY
Classification
Class III
Status
Terminated
Recall initiated
8 May 2023
FDA classified
19 May 2023
Reported
31 May 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects

Timeline

8 May 2023Recall initiated by company
19 May 2023Classified by FDA+11 days
31 May 2023Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, Intrasynovial and Soft Tissue Injection Only, Not for Intravenous Use, 1 mL Single Dose Vial, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Parenteral Unit, Ahmedabad 382213, India, Amneal Pharamceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1574-01.

Where it was distributed

Nationwide in the USA and PR

Nationwide Puerto Rico

Questions about this recall

Why was it recalled?

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Which lots are affected?

Lot Numbers: AP220481, Exp 09/2024; AP220536A, Exp 10/2024

Where was it sold?

Nationwide in the USA and PR

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Amneal Pharmaceuticals of New York

All 26

Other Methylprednisolone recalls

All 69